Emergent BioSolutions Inc. (NYSE: EBS) could soon see its opioid overdose drug made more widely available after a regulatory advisory panel endorsed its use as an emergency over-the-counter treatment. The Food and Drug Administration’s Nonprescription Drugs Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee voted in a joint meeting Wednesday to recommend that Narcan Nasal Spray, Emergent’s opioid overdose antidote currently available with a prescription, be made available without requiring a doctor’s order.
Emergent BioSolutions scores FDA advisory panel’s vote to sell opioid overdose drug Narcan without prescription
February 16, 2023